A phase 2 study of MKC-1 administered twice daily for 14 consecutive days every 4 weeks in patients with recurrent or resistant epithelial ovarian cancer or advanced endometrial cancer.

Trial Profile

A phase 2 study of MKC-1 administered twice daily for 14 consecutive days every 4 weeks in patients with recurrent or resistant epithelial ovarian cancer or advanced endometrial cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2014

At a glance

  • Drugs MKC 1 (Primary)
  • Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Sponsors CASI Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jan 2012 Actual patient number (44) added as reported by ClinicalTrials.gov.
    • 19 Jan 2012 Actual end date (1 Jan 2012 ) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top